The effects of lithium carbonate supplemented with nitrazepam on sleep disturbance during cannabis abstinence

Journal of Clinical Sleep Medicine

Volumn 11, Issue 10, 2015, Pages 1153-1162

  Allsop, David J ^a,f   Bartlett, Delwyn J ^b   Johnston, Jennifer ^c   Helliwell, David ^d   Winstock, Adam ^e   McGregor, Iain S ^a   Lintzeris, Nicholas ^a,f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

^d Drug and Alcohol North Coast Area   (Australia)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f SOUTH EASTERN SYDNEY LOCAL HEALTH DISTRICT   (Australia)

Author keywords

Actigraphy; Cannabis withdrawal; Cannabis withdrawal scale; Lithium; Nitrazepam; Pharmacotherapy; Sleep disturbance

Indexed keywords

LITHIUM CARBONATE; NITRAZEPAM; OXYTOCIN; TETRAHYDROCANNABINOL; CANNABIS; ENZYME INHIBITOR; HYPNOTIC SEDATIVE AGENT;

ACTIMETRY; ADULT; ARTICLE; CANNABIS ABSTINENCE; CANNABIS ADDICTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DETOXIFICATION; FEMALE; HELP SEEKING BEHAVIOR; HUMAN; INSOMNIA; MALE; NIGHT SWEAT; NIGHTMARE; OUTCOME ASSESSMENT; OXYTOCIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SLEEP EFFICIENCY; SLEEP FRAGMENTATION; SLEEP PARAMETERS; SLEEP PATTERN; SLEEP QUALITY; SLEEP TIME; SMOKING CESSATION; CHEMICALLY INDUCED; DRUG EFFECTS; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

ADULT; CANNABIS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; LITHIUM CARBONATE; MALE; NITRAZEPAM; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 84944673083     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.5090     Document Type: Article

References (43)

1. Bonn-Miller MO, Babson KA, Vujanovic AA, Feldner MT. Sleep problems and PTSD Symptoms interact to predict marijuana use coping motives: a preliminary investigation. J Dual Diagn 2010;6:111-22.
2. Babson KA, Boden MT, Harris AH, Stickle TR, Bonn-Miller MO. Poor sleep quality as a risk factor for lapse following a cannabis quit attempt. J Subst Abuse Treat 2013;44:438-43.
3. Brower KJ, Perron BE. Sleep disturbance as a universal risk factor for relapse in addictions to psychoactive substances. Med Hypotheses 2010;74:928-33.
4. Allsop DJ, Norberg MM, Copeland J, Fu S, Budney AJ. The cannabis withdrawal scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend 2011;119:123-9.
5. Allsop DJ, Copeland J, Norberg MM, et al. Quantifying the clinical signifcance of cannabis withdrawal. PLoS One 2012;7:e44864.
6. Budney AJ, Vandrey RG, Hughes JR, Thostenson JD, Bursac Z. Comparison of cannabis and tobacco withdrawal: severity and contribution to relapse. J Subst Abuse Treat 2008;35:362-8.
7. Copersino ML, Boyd SJ, Tashkin DP, et al. Cannabis withdrawal among non-treatment-seeking adult cannabis users. Am J Addict 2006;15:8-14.
8. Levin FR, Mariani JJ, Brooks DJ, Xie S, Murray KA. Delta9-tetrahydrocannabivarin testing may not have the sensitivity to detect marijuana use among individuals ingesting dronabinol. Drug Alcohol Depend 2010;106:65-8.
9. Allsop DJ, Copeland J, Lintzeris N, et al. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial. JAMA Psychiatry 2014;71:281-91.
10. Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend 2011;117:38-44.
11. Haney M, Hart CL, Vosburg SK, et al. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl) 2010;211:233-44.
12. Bolla KI, Lesage SR, Gamaldo CE, et al. Sleep disturbance in heavy marijuana users. Sleep 2008;31:901-8.
13. Bolla KI, Lesage SR, Gamaldo CE, et al. Polysomnogram changes in marijuana users who report sleep disturbances during prior abstinence. Sleep Med 2010;11:882-9.
14. Liappas J, Paparrigopoulos T, Tzavellas E, Christodoulou G. Alcohol detoxifcation and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. J Affect Disord 2003;76:279-84.
15. Cui S, Bowen RC, Gu G, Hannesson DK, Yu PH, Zhang X. Prevention of cannabinoid withdrawal syndrom by lithium: involvement of oxytocinergic neuronal activation. J Neurosci 2001;21:9867-76.
16. Winstock A, Lea T, Copeland J. Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study. J Psychopharmacol (Oxf) 2009;23:84-93.
17. Braga R, Panaitescu A, Badescu S, Zagrean A, Zagrean L. Intranasal administration of oxytocin alters sleep architechture. Biol Rhythm Res 2014;45:69-75.
18. McCall WV, Blocker JN, D'Agostino R Jr., et al. Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. Sleep Med 2010;11:822-7.
19. Billiard M. Lithium carbonate: effects on sleep patterns of normal and depressed subjects and its use in sleep-wake pathology. Pharmacopsychiatry 1987;20:195-6.
20. Johnston J, Lintzeris N, Allsop DJ, et al. Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. Psychopharmacology (Berl) 2014;231:4623-36.
21. Ellingsen P. Double-blind trial of triazolam 0.5 mg vs. nitrazepam 5 mg in outpatients. Acta Psychiatr Scand 1983;67:154-8.
22. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington DC: American Psychiatric Association, 1994.
23. Morgenthaler T, Alessi C, Friedman L, et al. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep 2007;30:519-29.
24. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 2000;48:555-60.
25. Lovibond SH, Lovibond PF. Manual for the depression anxiety and stress scales, 2nd ed. Sydney: Psychology Foundation, 1995.
26. Norberg MM, Mackenzie J, Copeland J. Quantifying cannabis use with the Timeline Followback approach: a psychometric evaluation. Drug Alcohol Depend 2012;121:247-52.
27. Carson DS, Bosanquet D P, Carter CS, Pournajaf-Nazarloo H, Blaszczynski A, McGregor IS. Preliminary evidence for lowered basal cortisol in a naturalistic sample of methamphetamine polydrug users. Exp Clin Psychopharmacol 2012;20:497-503.
28. Szeto A, McCabe PM, Nation DA, et al. Evaluation of enzyme immunoassay and radioimmunoassay methods for the measurement of plasma oxytocin. Psychosom Med 2011;73:393-400.
29. Bell ML, Fairclough DL. Practical and statistical issues in missing data for longitudinal patient reported outcomes. Stat Methods Med Res 2014;23:440-59.
30. Mallinckrodt CH, Clark SW, Carroll RJ, Molenbergh G. Assessing response profles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat 2003;13:179-90.
31. Rubin D. Inference and missing data. Biometrika 1976;63:581-92.
32. Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiatry 2006;19:233-8.
33. Budney AJ, Moore BA, Vandrey RG, Hughes JR. The time course and signifcance of cannabis withdrawal. J Abnorm Psychol 2003;112:393-402.
34. Loewen A, Siemens A, Hanly P. Sleep disruption in patients with sleep apnea and end-stage renal disease. J Clin Sleep Med 2009;5:324-9.
35. Thomas RJ. Sleep fragmentation and arousals from sleep-time scales, associations, and implications. Clin Neurophysiol 2006;117:707-11.
36. Sadeh A. The role and validity of actigraphy in sleep medicine: an update. Sleep Med Rev 2011;15:259-67.
37. Jacobus J, Bava S, Cohen-Zion M, Mahmood O, Tapert SF. Functional consequences of marijuana use in adolescents. Pharmacol Biochem Behav 2009;92:559-65.
38. Kaplan KA, McQuaid J, Primich C, Rosenlicht N. An evidence-based review of insomnia treatment in early recovery. J Addict Med 2014;8:389-94.
39. Morgan PT, Pace-Schott EF, Sahul ZH, Coric V, Stickgold R, Malison RT. Sleep, sleep-dependent procedural learning and vigilance in chronic cocaine users: evidence for occult insomnia. Drug Alcohol Depend 2006;82:238-49.
40. Stores G. Clinical diagnosis and misdiagnosis of sleep disorders. J Neurol Neurosurg Psychiatry 2007;78:1293-7.
41. Roth T. Does effective management of sleep disorders reduce substance dependence? Drugs 2009;69 Suppl 2:65-75.
42. Spruyt K, Gozal D, Dayyat E, Roman A, Molfese DL. Sleep assessments in healthy school-aged children using actigraphy: concordance with polysomnography. J Sleep Res 2011;20:223-32.
43. Marino M, Li Y, Rueschman MN, et al. Measuring sleep: accuracy, sensitivity, and specifcity of wrist actigraphy compared to polysomnography. Sleep 2013;36:1747-55.